BRAF and melanoma: In addition, melanomas that do not carry the BRAF oncogenes cannot be subjected to this type of therapy and are limited to treatments with immune checkpoint inhibitors, such as nivolumab, or combination of nivolumab with ipilimumab, approved by the FDA in 2016.